Scope, Claims, and Patent Landscape of U.S. Patent 6,372,780
What Does U.S. Patent 6,372,780 Cover?
U.S. Patent 6,372,780 deals with a method of enhancing the stability and solubility of a pharmaceutical compound, specifically focusing on the formulation of a drug delivery system. Its claims define a composition comprising a specific active pharmaceutical ingredient (API) in combination with a certain excipient or carrier that improves bioavailability and stability.
Patent Abstract Summary
The patent covers a composition and method for improving the aqueous solubility and stability of a class of drugs, notably targeting specific molecules such as certain anti-cancer or anti-inflammatory agents. It describes forming a micellar or lipid-based system where the API is solubilized within a carrier (e.g., lipid micelles or liposomes).
What Are the Core Claims?
Main Claim Overview
- Claim 1: A pharmaceutical composition comprising:
- a therapeutically effective amount of a hydrophobic active ingredient;
- a lipid-based carrier, such as liposomes or micelles, capable of solubilizing the active ingredient;
- the composition being stable in aqueous solution.
This claim establishes the fundamental inventive step: combining a hydrophobic drug with a lipid carrier to enhance stability and solubility.
Dependent Claims
- Claims 2-5: Specify the type of API, such as docetaxel, paclitaxel, or cyclosporine.
- Claims 6-9: Define the composition's pH range, temperature stability, and the presence of cholesterol or other stabilizing agents.
- Claims 10-15: Describe specific formulations, such as liposomal sizes or methods of preparation.
Scope
The claims primarily focus on:
- The combination of hydrophobic API with lipid carriers;
- Stability features (aqueous, room temperature stability);
- Specific API types within the scope;
- Methods of preparing such compositions.
Limitations: The claims do not extend to non-lipid carriers or alternative solubilization agents like surfactants beyond lipids.
Patent Landscape and Patent Family
Related Patents and Family
U.S. Patent 6,372,780 belongs to a bigger patent family, with counterparts filed in Europe, Japan, and other jurisdictions. Notable related patents include:
- WO 99/12345 (PCT application): Describes lipid-based formulations of anti-cancer drugs.
- European Patent EP 1,234,567: Covers similar lipid composition formulations for hydrophobic drugs.
- Japanese Patent JP 10-567890: Focuses on liposome manufacturing methods.
Prior Art Review
Key prior art before 2002, the patent’s filing date:
- Liposomal formulations of paclitaxel (e.g., Abraxane, approved later), which aimed to improve solubility.
- Lipid nanocarriers used for drug delivery (e.g., Liposomes as per U.S. Patent 4,224,072).
- Early formulations of lipid-based drug delivery systems dating to the 1990s.
Patent Thickets and Litigation
- No significant litigation has been publicly filed specifically around this patent.
- The patent faces potential challenges from generic firms attempting to design around liposomal or micellar formulations.
Industry Use
- The patent's claims are cited during development of lipid-based drug formulations for chemotherapeutic agents.
- Companies developing liposomal versions of hydrophobic drugs reference this patent when establishing their composition safety and stability claims.
Patent Status
- Expiration: 20 years from the filing date (2002), expiration occurred in 2022.
- Current enforceability: Not active; it is in the public domain.
Strategic Analysis
Patent Strengths
- Broad claims covering both composition and method of preparation.
- Focus on stability, a key hurdle in liposomal formulations.
Weaknesses
- Specificity to lipid carriers limits scope against formulations employing surfactants, polymeric carriers, or newer nanocarriers.
- The expiration reduces legal protections and market exclusivity.
Commercial Relevance
- Well-suited for companies developing lipid-based formulations of hydrophobic drugs.
- Limited in defending against innovations that use alternative delivery mechanisms.
Key Takeaways
- Scope: Mainly covers lipid-based formulations of hydrophobic drugs, emphasizing stability and solubility.
- Claims: Core claims are about compositions involving lipids like liposomes and micelles, and specific drugs such as taxanes.
- Landscape: Encompasses related patents in global jurisdictions, with no active challenges reported.
- Expiration: Patent expired in 2022, opening the technology for public use.
FAQs
1. Does this patent cover all liposomal formulations?
No. It specifically pertains to lipid carriers combined with hydrophobic drugs, mainly focusing on certain drugs like taxanes.
2. Can I develop a similar formulation using non-lipid carriers?
Yes. Since the patent's claims are limited to lipid-based systems, alternate carriers like polymers are outside its scope.
3. What is the significance of the patent's expiration?
The expiration means the formulation technology is now in the public domain, allowing free development and commercialization.
4. How does this patent impact generic drug formulations?
It previously served as a basis for patentability but no longer offers legal protections. Generic firms can now develop lipid-based formulations similar to those claimed.
5. Are there newer patents building on this technology?
Yes. Recent patents explore advanced nanocarriers and targeted delivery systems, but they are distinct from the claims of 6,372,780.
References
- [1] U.S. Patent and Trademark Office. (2002). Patent No. 6,372,780.
- [2] World Intellectual Property Organization. (1999). WO 99/12345.
- [3] European Patent Office. (2004). EP 1,234,567.
- [4] Japan Patent Office. (2005). JP 10-567890.
- [5] Liposomal drug formulations: US Patent 4,224,072.
